8-K: Clene Inc. Amends Supply and License Agreements with 4Life Research, LLC

Clene Inc. has amended and restated its exclusive supply and license agreements with 4Life Research, LLC, an international health supplement supplier and related party, extending the partnership through 2033.

Summary

• Clene Inc. and its subsidiary, Clene Nanomedicine, Inc., have entered into amended and restated exclusive supply and license agreements with 4Life Research, LLC.
• The original agreements were established in August 2018.
• Under the supply agreement, 4Life will exclusively purchase dietary supplement and non-pharmaceutical products from Clene.
• The purchase price will be Clene's cost plus 20%.
• 4Life has minimum sales commitments for the years 2024 through 2033, starting at $5 million in 2024 and increasing to $20.5 million in 2033.
• The license agreement grants 4Life an exclusive, royalty-bearing license to use, sell, and commercialize the licensed products.
• 4Life will pay Clene a 3% royalty on incremental sales of licensed products.
• Clene may sell licensed products through third-party retail outlets or its own websites starting January 1, 2027.
• Both agreements will continue until December 31, 2033, with options for five-year renewals.
• Clene waived a $960,077.32 payment that 4Life was previously obligated to pay.

Sentiment

Score: 7

Explanation: The document indicates a positive development with the extension of a key partnership, but there are some risks and limitations to consider. The sentiment is moderately positive.

Positives

• The amended agreements extend the partnership with 4Life through 2033, providing long-term revenue potential.
• The cost-plus pricing model ensures a consistent profit margin for Clene.
• The minimum sales commitments provide a baseline for expected revenue from 4Life.
• The royalty structure allows Clene to benefit from 4Life's sales growth.
• Clene gains the ability to sell products through additional channels starting in 2027, diversifying its sales strategy.
• The waiver of the $960,077.32 payment indicates a strong and ongoing relationship between the parties.

Negatives

• Clene's reliance on 4Life for sales of the licensed products could be a risk if 4Life's performance declines.
• The 3% royalty rate may be considered low compared to other licensing agreements.
• The minimum sales commitments are not guaranteed and could be missed, potentially impacting Clene's revenue.
• Clene's ability to sell through other channels is restricted until 2027.

Risks

• Failure by 4Life to meet minimum sales commitments could lead to a loss of exclusivity for 4Life.
• The agreements are subject to termination for material breaches, insolvency, or bankruptcy.
• Clene's ability to manufacture and supply the required quantities of licensed products is critical to the success of the agreement.
• Changes in the regulatory environment could impact the sale and distribution of the licensed products.
• The agreements are subject to cross termination if either the supply or license agreement is terminated.

Future Outlook

The amended agreements provide a framework for a long-term partnership between Clene and 4Life through 2033, with potential for revenue growth based on 4Life's sales performance and Clene's ability to expand its sales channels starting in 2027.

Industry Context

This announcement reflects a continued trend of pharmaceutical and biotech companies partnering with established distribution networks to commercialize their products. The health supplement market is competitive, and this agreement allows Clene to leverage 4Life's existing infrastructure and customer base.

Comparison to Industry Standards

• The cost-plus pricing model is a common practice in supply agreements, ensuring a consistent profit margin for the supplier.
• Royalty rates in licensing agreements vary widely depending on the industry, product, and exclusivity, with 3% being on the lower end for exclusive licenses.
• Minimum sales commitments are a standard feature in distribution agreements, providing a level of revenue assurance for the supplier.
• The length of the agreement, extending through 2033, is typical for long-term strategic partnerships.
• Comparable companies in the health supplement space often have similar distribution agreements with exclusivity clauses and minimum sales targets.

Related Party Transactions

• 4Life Research, LLC is a stockholder and related party of Clene Inc.

Stakeholder Impact

• Shareholders may view the extended partnership positively, potentially increasing the share price.
• Employees of Clene may benefit from the increased revenue and stability provided by the agreement.
• 4Life's distributors and customers will continue to have access to Clene's products.
• Suppliers to Clene may see increased demand for their products.

Next Steps

• 4Life will begin purchasing licensed products from Clene under the new terms.
• 4Life will work to meet the minimum sales commitments outlined in the agreement.
• Clene will continue to manufacture and supply the licensed products to 4Life.
• Clene will prepare to expand its sales channels starting in 2027.

Key Dates

Keywords

supply agreement, license agreement, dietary supplements, non-pharmaceutical products, royalty, minimum sales commitment, exclusive rights, Clene, 4Life, nanomedicine